Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts - PubMed (original) (raw)
- PMID: 6579344
Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts
W T Beck et al. Mol Pharmacol. 1983 Nov.
Abstract
We studied the accumulation of [3H]vinblastine (VLB) by lines of CCRF-CEM cultured human leukemic lymphoblasts that were either sensitive or resistant to the drug. Neither cell line metabolized VLB, nor selectively retained any radioactive impurities. There was an apparent "instantaneous" accumulation of VLB by cells of both lines, resulting in cell to medium ratios greater than 1.0 within 1 sec after drug addition. Experiments between 0 and 60 sec revealed that the presumed undirectional initial rate of VLB accumulation by resistant cells, termed CEM/VLB100, was about one-half that of sensitive CEM cells. In experiments carried out over 60 min, the VLB-resistant cells accumulated considerably less [3H]VLB than did the sensitive cells. Drug accumulation by both cell lines was temperature-sensitive, since incubation of cells at 4 degrees resulted in only minimal uptake beyond that observed at zero time. CEM/VLB100 cells retained less drug than did CEM cells, apparently because of a larger fraction of readily releasable VLB compared with CEM cells. The accumulation of VLB by either cell line was related in part to cellular levels of ATP. Although depletion of ATP was associated with decreased accumulation of VLB by CEM cells, it was related to enhanced drug accumulation by CEM/VLB100 cells. Restoration of ATP levels to near control values by addition of glucose also had opposite effects on the two cell lines, causing further accumulation of VLB by the sensitive line but leading to apparent drug efflux from the resistant line. Potentially competing substrates (VM-26, colchicine, daunorubicin, and doxorubicin) failed to block this glucose-mediated release of VLB from the CEM/VLB100 cells. In experiments with energy-depleted CEM/VLB100 cells preloaded with VLB and then incubated in drug-free medium, initial drug loss was shown to be independent of cellular metabolism, being roughly the same for both metabolically intact and metabolically depleted cells. Glucose (energy) was required only for subsequent release of what appeared to be a more tightly bound cell-associated fraction of VLB. Results of zero-time binding studies tended to confirm that VLB binding by resistant cells has two components, one requiring and the other not requiring metabolic energy. Differences in the proportions of these two components between the sensitive and resistant cells suggest a mechanism for resistance to VLB and similar compounds.
Similar articles
- Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil.
Beck WT, Cirtain MC, Look AT, Ashmun RA. Beck WT, et al. Cancer Res. 1986 Feb;46(2):778-84. Cancer Res. 1986. PMID: 3455678 - Secretion of lysosomal enzymes by drug-sensitive and multiple drug-resistant cells.
Warren L, Jardillier JC, Ordentlich P. Warren L, et al. Cancer Res. 1991 Apr 15;51(8):1996-2001. Cancer Res. 1991. PMID: 1672622 - Vinca alkaloid-resistant phenotype in cultured human leukemic lymphoblasts.
Beck WT. Beck WT. Cancer Treat Rep. 1983 Oct;67(10):875-82. Cancer Treat Rep. 1983. PMID: 6354435 Review. No abstract available. - Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics.
Tsuruo T. Tsuruo T. Cancer Treat Rep. 1983 Oct;67(10):889-94. Cancer Treat Rep. 1983. PMID: 6354436 Review.
Cited by
- Relationship between the cellular accumulation and the cytotoxicity of S12363, a new Vinca alkaloid derivative.
Pierré A, Pérez V, Léonce S, Boutin JA, Saint-Dizier D, Hautefaye P, Lavielle G, Atassi G. Pierré A, et al. Cancer Chemother Pharmacol. 1992;29(5):367-74. doi: 10.1007/BF00686005. Cancer Chemother Pharmacol. 1992. PMID: 1551175 - Modulation of vinblastine sensitivity by dipyridamole in multidrug resistant fibrosarcoma cells lacking mdr1 expression.
Shalinsky DR, Slovak ML, Howell SB. Shalinsky DR, et al. Br J Cancer. 1991 Oct;64(4):705-9. doi: 10.1038/bjc.1991.385. Br J Cancer. 1991. PMID: 1680368 Free PMC article. - Verapamil increases the sensitivity of primary human colorectal carcinoma tissue to vincristine.
Ince P, Appleton DR, Finney KJ, Sunter JP, Watson AJ. Ince P, et al. Br J Cancer. 1986 Jan;53(1):137-9. doi: 10.1038/bjc.1986.19. Br J Cancer. 1986. PMID: 3947510 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical